Clinical Trials Logo

Marfan Syndrome clinical trials

View clinical trials related to Marfan Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01361087 Withdrawn - Marfan Syndrome Clinical Trials

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

Start date: April 2011
Phase: Phase 3
Study type: Interventional

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice.